Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Suneel Gupta Biography and Net Worth

Chief Development Officer of Protagonist Therapeutics

Dr. Gupta joined as Chief Development Officer in Jan 2019. Dr. Gupta serves on the scientific advisory boards of several pharmaceutical companies. Prior to joining Protagonist, he was Chief Scientific Officer (CSO) of Impax Pharmaceuticals from 2008 to 2019. Prior to Impax, he was Senior Vice President (SVP) and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002-2008. Prior to J&J, he was at ALZA from 1989-2001, where he had increasing levels of responsibility until promoted to Vice President of Clinical Pharmacology & Product Discovery. Dr. Gupta received his PhD in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco.

What is Suneel Gupta's net worth?: The estimated net worth of Suneel Gupta is at least $7.62 million as of January 9th, 2024. Dr. Gupta owns 187,567 shares of Protagonist Therapeutics stock worth more than $7,624,599 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Gupta may own. Additionally, Dr. Gupta receives a salary of $719,210.00 as Chief Development Officer at Protagonist Therapeutics. Learn More about Suneel Gupta's net worth.
How old is Suneel Gupta?: Dr. Gupta is currently 66 years old. There are 6 older executives and no younger executives at Protagonist Therapeutics. The oldest executive at Protagonist Therapeutics is Dr. Dinesh V. Patel Ph.D., CEO, President, Secretary & Director, who is 67 years old. Learn More on Suneel Gupta's age.
What is Suneel Gupta's salary?: As the Chief Development Officer of Protagonist Therapeutics, Inc., Dr. Gupta earns $719,210.00 per year. The highest earning executive at Protagonist Therapeutics is Dr. Dinesh V. Patel Ph.D., CEO, President, Secretary & Director, who commands a salary of $1,030,000.00 per year. Learn More on Suneel Gupta's salary.
How do I contact Suneel Gupta?: The corporate mailing address for Dr. Gupta and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on Suneel Gupta's contact information.
Has Suneel Gupta been buying or selling shares of Protagonist Therapeutics?: Suneel Gupta has not been actively trading shares of Protagonist Therapeutics during the last quarter. Most recently, Suneel Gupta sold 5,000 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $25.00, for a transaction totalling $125,000.00. Following the completion of the sale, the insider now directly owns 187,567 shares of the company's stock, valued at $4,689,175. Learn More on Suneel Gupta's trading history.
Who are Protagonist Therapeutics' active insiders?: Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Dinsesh Patel (CEO), and William Waddill (Director). Learn More on Protagonist Therapeutics' active insiders.
Are insiders buying or selling shares of Protagonist Therapeutics?: In the last year, insiders at the sold shares 12 times. They sold a total of 163,566 shares worth more than $5,579,977.11. The most recent insider tranaction occured on November, 15th when insider Arturo Md Molina sold 1,906 shares worth more than $78,107.88. Insiders at Protagonist Therapeutics own 5.4% of the company. Learn More about insider trades at Protagonist Therapeutics.
Information on this page was last updated on 11/15/2024.

Suneel Gupta Insider Trading History at Protagonist Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/9/2024	Sell	5,000	$25.00	$125,000.00	187,567
12/3/2019	Buy	30,000	$5.13	$153,900.00	389,824

Suneel Gupta Buying and Selling Activity at Protagonist Therapeutics

Protagonist Therapeutics Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $40.65

$37.80

$41.18

50 Day Range

MA: $45.43

$38.65

$48.43

2 Week Range

Now: $40.65

$16.80

$48.89

Volume

1,048,365 shs

Average Volume

669,015 shs

Market Capitalization

$2.42 billion

P/E Ratio

15.28

Dividend Yield

N/A

Beta

2.17

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Suneel Gupta Biography and Net Worth

What is Suneel Gupta's net worth?

How old is Suneel Gupta?

What is Suneel Gupta's salary?

How do I contact Suneel Gupta?

Has Suneel Gupta been buying or selling shares of Protagonist Therapeutics?

Who are Protagonist Therapeutics' active insiders?

Are insiders buying or selling shares of Protagonist Therapeutics?